Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001558370-24-011795
Filing Date
2024-08-12
Accepted
2024-08-12 07:06:29
Documents
86
Period of Report
2024-06-30

Document Format Files

Seq Description Document Type Size
1 10-Q ymab-20240630x10q.htm   iXBRL 10-Q 1953512
2 EX-31.1 ymab-20240630xex31d1.htm EX-31.1 15597
3 EX-31.2 ymab-20240630xex31d2.htm EX-31.2 15590
4 EX-32.1 ymab-20240630xex32d1.htm EX-32.1 7838
5 EX-32.2 ymab-20240630xex32d2.htm EX-32.2 7850
  Complete submission text file 0001558370-24-011795.txt   8846492

Data Files

Seq Description Document Type Size
6 EX-101.SCH ymab-20240630.xsd EX-101.SCH 63083
7 EX-101.CAL ymab-20240630_cal.xml EX-101.CAL 48568
8 EX-101.DEF ymab-20240630_def.xml EX-101.DEF 274289
9 EX-101.LAB ymab-20240630_lab.xml EX-101.LAB 514269
10 EX-101.PRE ymab-20240630_pre.xml EX-101.PRE 438406
89 EXTRACTED XBRL INSTANCE DOCUMENT ymab-20240630x10q_htm.xml XML 1666501
Mailing Address 230 PARK AVENUE SUITE 3350 NEW YORK NY 10169
Business Address 230 PARK AVENUE SUITE 3350 NEW YORK NY 10169 212-847-9841
Y-mAbs Therapeutics, Inc. (Filer) CIK: 0001722964 (see all company filings)

EIN.: 474619612 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-38650 | Film No.: 241194712
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)